Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.

中文翻译：

---

ChAdOx1 nCoV-19/AZD1222 疫苗表达的类天然 SARS-CoV-2 刺突糖蛋白


针对 SARS-CoV-2 病毒的疫苗开发重点关注中和免疫反应的主要目标，即刺突 (S) 糖蛋白。腺病毒载体疫苗为病毒抗原的传递提供了一个有效的平台，但对于中和抗体的产生很重要，它们产生适当加工和组装的病毒抗原，模仿在 SARS-CoV-2 病毒上观察到的病毒抗原。在这里，我们描述了腺病毒载体 ChAdOx1 nCoV-19/AZD1222 疫苗衍生的 S 蛋白的结构、构象和糖基化。我们展示了类似天然的翻译后加工和组装，并揭示了采用三聚体预融合构象的细胞表面上 S 蛋白的表达。这里提供的数据证实了 ChAdOx1 腺病毒载体作为 SARS-CoV-2 疫苗的领先平台技术的使用。